Quasi Experiment of Prenatal Probiotics Against Group B Streptococcus Colonization

Completed · Not applicable

Conditions studied: Pregnancy

In brief

This pilot quasi experiment was designed to determine the feasibility of a randomized controlled trial of the oral probiotic combination of Florajen3 (\>7.5 x109 L. acidophilus, \>6.0 x109. B. lactis, and \>1.5 x109 B. longum) taken orally once daily beginning at 28 weeks gestation, against placebo, to reduce the colonization of group B Streptococcus at 36 weeks.

Key facts

Study ID

NCT02249325

Run by

Marquette University

People needed

20

Starts

2011-01-01

Expected to finish

2013-06-01

Last updated by the study team

2014-10-07

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Low risk pregnancy (no obstetric, fetal, medical or genetic risk factors)
• Adult (≥18 years of age)
• Pregnant at 28 ± 2 weeks gestation
• Able to speak and write English
• Willingness to participate in the study intervention (oral probiotic) and data collection (including vaginal and rectal swabs and questionnaires)

You may not qualify if…

• Pregnant women with obstetric, fetal, medical, or genetic risk factors.
• <18 years of age

Where it is running

• Aurora Healthcare — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.